Mezrich R
Department of Radiology, Robert Wood Johnson Medical School, Radiology Group of New Brunswick, New Jersey, USA.
Magn Reson Imaging Clin N Am. 1994 May;2(2):211-43.
We have discussed the importance of staging in making decisions about the type and extent of surgery and in determining prognosis, and at the same time have noted the remarkably poor accuracy of clinical staging. We have detailed the present and potential accuracy of MR imaging for assessing size and extent of tumor and its advantages compared to clinical and other (primarily CT) staging. The question that naturally arises is that if MR imaging is so good, why isn't it used more often? In a critical review of the use of CT for staging, Moore et al noted that "Ultimately, a diagnostic test can be considered useful only if it provides information leading to a change in therapy with patient benefit." In a retrospective review of 246 patients divided into those who did and those who did not undergo pretreatment CT, they found that only 8 patients had improved survival from treatment modifications based on CT, while in the same group 8 patients underwent additional surgical procedures because of CT findings that proved to be erroneous. They concluded that "Considering the high cost and limited benefit, CT for cervical cancer staging is not recommended." Although this sort of critical outcome analysis has not yet been done for MR imaging, it is evident from our discussion that MR imaging has much to offer that CT does not, and that MR imaging can indeed provide information leading to a change in therapy. Unlike CT, MR imaging can measure accurately the size of the tumor, determine whether or not it is confined within the cervix, and determine extension to the vagina, parametrium, or myometrium. MR imaging even has advantages in assessing lymph node involvement and is particularly recommended when clinical tumor diameter approaches 3 cm, in which case the incidence of lymph node metastasis approaches 50%. With rapid improvements in techniques and hardware, especially dedicated coils, fast acquisition pulse sequences, and dynamic enhancement methods, it can be expected that MR imaging will become even more accurate in identifying and staging disease. Given this, the question still remains as to why MR imaging is not used more in the work-up of patients with cervical cancer. In part this may be caused by na lack of awareness by clinicians of the advantages of MR imaging in this application. In part this may be caused by limited availability of MR imaging systems, although by now most midsized and probably all large hospitals have at least one MR imaging unit.(ABSTRACT TRUNCATED AT 400 WORDS)
我们已经讨论了分期在决定手术类型和范围以及确定预后方面的重要性,同时也注意到临床分期的准确性非常差。我们详细阐述了磁共振成像(MR成像)在评估肿瘤大小和范围方面目前的及潜在的准确性,以及与临床分期和其他(主要是CT)分期相比它的优势。自然而然会出现的问题是,如果MR成像如此出色,为什么它没有被更频繁地使用呢?在对CT用于分期的批判性综述中,摩尔等人指出:“最终,只有当一种诊断测试能提供导致治疗改变并使患者受益的信息时,它才会被认为是有用的。”在对246例患者进行的回顾性研究中,这些患者被分为接受和未接受治疗前CT检查的两组,他们发现只有8例患者因基于CT的治疗调整而提高了生存率,而在同一组中,有8例患者由于CT检查结果被证明有误而接受了额外的手术。他们得出结论:“考虑到高成本和有限的益处,不建议将CT用于宫颈癌分期。”虽然尚未对MR成像进行这种批判性的结果分析,但从我们的讨论中可以明显看出,MR成像有许多CT所没有的优势,并且MR成像确实可以提供导致治疗改变的信息。与CT不同,MR成像能够准确测量肿瘤大小,确定肿瘤是否局限于宫颈内,以及确定肿瘤向阴道、宫旁组织或子宫肌层的浸润情况。MR成像在评估淋巴结受累方面甚至也有优势,当临床肿瘤直径接近3厘米时尤其推荐使用,在这种情况下淋巴结转移的发生率接近50%。随着技术和硬件的快速改进,特别是专用线圈、快速采集脉冲序列和动态增强方法,预计MR成像在识别疾病和进行分期方面将变得更加准确。鉴于此,MR成像在宫颈癌患者检查中未被更广泛使用的问题仍然存在。部分原因可能是临床医生没有意识到MR成像在该应用中的优势。部分原因可能是MR成像系统的可及性有限,尽管到目前为止大多数中型医院以及可能所有大型医院都至少有一台MR成像设备。(摘要截取自400字)